Central Delivery of Dicer-substrate siRNA: A Direct Application for Pain Research

RNA interference (RNAi) is gaining acceptance as a potential therapeutic strategy against peripheral disease, and several clinical trials are already underway with 21-mer small-interfering RNA (siRNA) as the active pharmaceutical agent. However, for central affliction like pain, such innovating ther...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular therapy 2008-07, Vol.16 (7), p.1331-1339
Hauptverfasser:	Doré-Savard, Louis, Roussy, Geneviève, Dansereau, Marc-André, Collingwood, Michael A, Lennox, Kim A, Rose, Scott D, Beaudet, Nicolas, Behlke, Mark A, Sarret, Philippe
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenosine Analgesics Animals Biophysics CHO Cells Clinical trials Cricetinae Cricetulus Drug dosages Ganglia, Spinal - metabolism Gene therapy Health sciences Lipids Male Oligonucleotides - administration & dosage Oligonucleotides - therapeutic use Pain Pain - drug therapy Physiology Proteins Rats Rats, Sprague-Dawley Receptors, Neurotensin - antagonists & inhibitors Research methodology Ribonuclease III - metabolism RNA Interference RNA, Small Interfering - administration & dosage RNA, Small Interfering - metabolism RNA, Small Interfering - therapeutic use Spinal cord
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!